Analysis of NF-B signaling pathways by proteomic approaches

Expert Review of Proteomics

Volumn 7, Issue 2, 2010, Pages 189-203

  Niederberger, Ellen ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cancer; Inflammation; NF B; Proteomics

Indexed keywords

AMINO ACID; ANTIBODY; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; POLYUBIQUITIN; RESVERATROL; STABLE ISOTOPE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANALYSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER RESEARCH; CELL CULTURE; CLINICAL RESEARCH; ESOPHAGUS CANCER; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; ISOTOPE LABELING; LIVER CELL CARCINOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROSTATE CANCER; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; TWO HYBRID SYSTEM; YEAST; ANIMAL; BIOLOGICAL MODEL; GENETICS; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 77950825833     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.1     Document Type: Review

References (105)

1. Karin M, Yamamoto Y, Wang QM. The IKK NF-kB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3(1), 17-26 (2004).
2. Yamamoto Y, Gaynor RB. IkB kinases: key regulators of the NF-kB pathway. Trends Biochem. Sci. 29(2), 72-79 (2004).
3. Pahl HL. Activators and target genes of Rel/NF-kB transcription factors. Oncogene 18(49), 6853-6866 (1999).
4. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006(357), re13 (2006).
5. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30(1), 43-52 (2005).
6. Peters RT, Maniatis T. A new family of IKK-related kinases may function as IkB kinase kinases. Biochim. Biophys. Acta 1471(2), M57-M62 (2001).
7. Shimada T, Kawai T, Takeda K et al. IKK-I, a novel lipopolysaccharide- inducible kinase that is related to IkB kinases. Int. Immunol. 11(8), 1357-1362 (1999).
8. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 300(5622), 1148-1151 (2003).
9. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc. Natl Acad. Sci. USA 101(1), 233-238 (2004).
10. Buss H, Dorrie A, Schmitz ML, Hoffmann E, Resch K, Kracht M. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-kB at serine 536 is mediated by multiple protein kinases including IkB kinase (IKK)-a, IKKb, IKKe, TRAF family member-associated (TANK)- binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J. Biol. Chem. 279(53), 55633-55643 (2004).
11. Adli M, Baldwin AS. IKK-I/IKKe controls constitutive, cancer cell-associated NF-B activity via regulation of Ser-536 p65/RelA phosphorylation. J. Biol. Chem. 281, 26976-26984 (2006).
12. Mattioli I, Geng H, Sebald A et al. Inducible phosphorylation of NF-kB p65 at serine 468 by T cell costimulation is mediated by IKK e. J. Biol. Chem. 281(10), 6175-6183 (2006).
13. Harris J, Oliere S, Sharma S et al. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK e. J. Immunol. 177(4), 2527-2535 (2006).
14. Monaco C, Paleolog E. Nuclear factor kB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc. Res. 61(4), 671-682 (2004).
15. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-kB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 105(12), 1799 - 1806 (2000).
16. Basseres DS, Baldwin AS. Nuclear factor-kB and inhibitor of kB kinase pathways in oncogenic initiation and progression. Oncogene 25(51), 6817-6830 (2006).
17. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kB. Oncogene 25(51), 6800-6816 (2006).
18. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003).
19. Banks RE, Dunn MJ, Hochstrasser DF et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 356(9243), 1749-1756 (2000).
20. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell Proteomics 3(5), 490-500 (2004).
21. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250(10), 4007-4021 (1975).
22. Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell Proteomics 1(2), 117-124 (2002).
23. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60(20), 2299-2301 (1988).
24. Whitehouse CM, Dreyer RN, Yamashita M, Fenn JB. Electrospray interface for liquid chromatographs and mass spectrometers. Anal. Chem. 57(3), 675-679 (1985).
25. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21(6), 1164-1177 (2000).
26. Falk R, Ramstrom M, Stahl S, Hober S. Approaches for systematic proteome exploration. Biomol. Eng. 24(2), 155-168 (2007).
27. Fournier ML, Gilmore JM, Martin-Brown SA, Washburn MP. Multidimensional separations-based shotgun proteomics. Chem. Rev. 107(8), 3654-3686 (2007).
28. Zhu H, Bilgin M, Snyder M. Proteomics. Annu. Rev. Biochem. 72, 783-812 (2003).
29. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2(2), RESEARCH0004 (2001).
30. Knezevic V, Leethanakul C, Bichsel VE et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1(10), 1271-1278 (2001).
31. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16), 1981-1989 (2001).
32. Schubert W, Bonnekoh B, Pommer AJ et al. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat. Biotechnol. 24(10), 1270-1278 (2006).
33. Linke B, Pierre S, Coste O et al. Toponomics analysis of drug-induced changes in arachidonic acid-dependent signaling pathways during spinal nociceptive processing. J. Proteome Res. 8(10), 4851-4859 (2009).
34. Chien CT, Bartel PL, Sternglanz R, Fields S. The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc. Natl Acad. Sci. USA 88(21), 9578-9582 (1991).
35. Puig O, Caspary F, Rigaut G et al. The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 24(3), 218-229 (2001).
36. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, Seraphin B. A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 17(10), 1030-1032 (1999).
37. Bauch A, Superti-Furga G. Charting protein complexes, signaling pathways, and networks in the immune system. Immunol. Rev. 210, 187-207 (2006).
38. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics 1(5), 376-386 (2002).
39. Tanaka M, Fuentes ME, Yamaguchi K et al. Embryonic lethality, liver degeneration, and impaired NF-kB activation in IKK-b-deficient mice. Immunity 10(4), 421-429 (1999).
40. Rudolph D, Yeh WC, Wakeham A et al. Severe liver degeneration and lack of NF-kB activation in NEMO/IKKg-deficient mice. Genes Dev. 14(7), 854-862 (2000).
41. Li Q, Lu Q, Hwang JY et al. IKK1- deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13(10), 1322-1328 (1999).
42. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kB. Nature 376(6536), 167-170 (1995).
43. Kassed CA, Willing AE, Garbuzova- Davis S, Sanberg PR, Pennypacker KR. Lack of NF-kB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp. Neurol. 176(2), 277-288 (2002).
44. Hansen JM, Moriarty-Craige S, Jones DP. Nuclear and cytoplasmic peroxiredoxin-1 differentially regulate NF-kB activities. Free Radic. Biol. Med. 43(2), 282-288 (2007).
45. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O. Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. J. Clin. Lab. Anal. 13(6), 280-286 (1999).
46. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 22(7), 340-345 (2004).
47. Owen JB, Opii WO, Ramassamy C, Pierce WM, Butterfield DA. Proteomic analysis of brain protein expression levels in NF-kb p50-/- homozygous knockout mice. Brain Res. 1240, 22-30 (2008).
48. Pejovic V, Soskic V, Pan W, Kastin AJ. Brain proteome of mice lacking the receptors for tumor necrosis factor a. Proteomics 4(5), 1461-1464 (2004).
49. Bouwmeester T, Bauch A, Ruffner H et al. A physical and functional map of the human TNF-a/NF-kB signal transduction pathway. Nat. Cell Biol. 6(2), 97-105 (2004).
50. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit. Care Med. 29(7 Suppl.), S21-S27 (2001).
51. Tseng HW, Juan HF, Huang HC et al. Lipopolysaccharide-stimulated responses in rat aortic endothelial cells by a systems biology approach. Proteomics 6(22), 5915-5928 (2006).
52. Metzner J, Popp L, Marian C et al. The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J. Mol. Med. 85(6), 623-633 (2007).
53. Wang T, Gu S, Ronni T, Du YC, Chen X. In vivo dual-tagging proteomic approach in studying signaling pathways in immune response. J. Proteome Res. 4(3), 941-949 (2005).
54. Wang T, Chuang TH, Ronni T et al. Flightless I homolog negatively modulates the TLR pathway. J. Immunol. 176(3), 1355-1362 (2006).
55. Dhungana S, Merrick BA, Tomer KB, Fessler MB. Quantitative proteomics analysis of macrophage rafts reveals compartmentalized activation of the proteasome and of proteasome-mediated ERK activation in response to lipopolysaccharide. Mol. Cell Proteomics 8(1), 201-213 (2009).
56. Alejo A, Ruiz-Arguello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc. Natl Acad. Sci. USA 103(15), 5995-6000 (2006).
57. Mohamed MR, Rahman MM, Lanchbury JS et al. Proteomic screening of variola virus reveals a unique NF-kB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc. Natl Acad. Sci. USA 106(22), 9045-9050 (2009).
58. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kB regulation in rheumatoid arthritis and murine collagen-induced arthritis. AutoImmunity 28(4), 197-208 (1998).
59. Sekigawa I, Yanagida M, Iwabuchi K et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-a antibody therapy. Clin. Exp. Rheumatol. 26(2), 261-267 (2008).
60. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932-1939 (1999).
61. Andreas K, Lubke C, Haupl T et al. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res. Ther. 10(1), R9 (2008).
62. Cornett WR, Sharma AK, Day TA et al. Anaplastic thyroid carcinoma: an overview. Curr. Oncol. Rep. 9(2), 152-158 (2007).
63. Pacifico F, Mauro C, Barone C et al. Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. J. Biol. Chem. 279(52), 54610-54619 (2004).
64. Pacifico F, Paolillo M, Chiappetta G et al. RbAp48 is a target of nuclear factor-kB activity in thyroid cancer. J. Clin. Endocrinol. Metab. 92(4), 1458-1466 (2007).
65. Iannetti A, Pacifico F, Acquaviva R et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl Acad. Sci. USA 105(37), 14058-14063 (2008).
66. Hortobagyi GN, de la Garza Salazar J, Pritchard K et al. The global breast cancer burden: variations in epidemiology and survival. Clin. Breast Cancer 6(5), 391-401 (2005).
67. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2(3), REVIEWS3005 (2001).
68. Dickson C, Spencer-Dene B, Dillon C, Fantl V. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res. 2(3), 191-196 (2000).
69. Takei Y, Kurobe M, Uchida A, Hayashi K. Serum concentrations of basic fibroblast growth factor in breast cancer. Clin. Chem. 40(10), 1980-1981 (1994).
70. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kB activation induced via interaction between Akt and IkB kinase-b in breast cancer cells. Oncogene 24(35), 5482-5491 (2005).
71. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat. Rev. Cancer 7(10), 750-762 (2007).
72. Cecconi D, Zamo A, Bianchi E et al. Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 8(21), 4495-4506 (2008).
73. Martinez N, Camacho FI, Algara P et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 63(23), 8226-8232 (2003).
74. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171(1), 88-95 (2003).
75. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70(5), 700-713 (2005).
76. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non- Hodgkin's lymphoma. Int. J. Cancer 119(5), 971-979 (2006).
77. Cecconi D, Zamo A, Parisi A et al. Induction of apoptosis in Jeko-1 mantle cell lymphoma cell line by resveratrol: a proteomic analysis. J. Proteome Res. 7(7), 2670-2680 (2008).
78. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17(14), 1975-1985 (2003).
79. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol. 179(3), 297-304 (1999).
80. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 59(23), 5892-5895 (1999). (Pubitemid 30004946)
81. Tsan MF, White JE, Maheshwari JG, Chikk G. Anti-leukemia effect of resveratrol. Leuk. Lymphoma 43(5), 983-987 (2002).
82. Bhardwaj A, Sethi G, Vadhan-Raj S et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109(6), 2293-2302 (2007).
83. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non- Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. 3(1), 71-84 (2004).
84. Tomsig JL, Sohma H, Creutz CE. Calcium-dependent regulation of tumour necrosis factor-a receptor signalling by copine. Biochem. J. 378(Pt 3), 1089-1094 (2004).
85. Kundu JK, Surh YJ. Molecular basis of chemoprevention by resveratrol: NF-kB and AP-1 as potential targets. Mutat. Res. 555(1-2), 65-80 (2004).
86. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31(4), 339-346 (2002).
87. Lee TH, Tai DI, Cheng CJ et al. Enhanced nuclear factor-kB-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics. J. Biomed. Sci. 13(1), 27-39 (2006).
88. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 434(7035), 843-850 (2005). (Pubitemid 40558990)
89. The World Cancer Report - the major findings. Cent. Eur. J. Public Health 11(3), 177-179 (2003).
90. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev. Proteomics 2(3), 337-348 (2005).
91. Feng W, Brown RE, Trung CD et al. Morphoproteomic profile of mTOR, Ras/ Raf kinase/ERK, and NF-kB pathways in human gastric adenocarcinoma. Ann. Clin. Lab. Sci. 38(3), 195-209 (2008).
92. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat. Rev. 29(6), 525-532 (2003).
93. Uemura N, Nakanishi Y, Kato H, Nagino M, Hirohashi S, Kondo T. Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-kB pathway and mitotic checkpoint. Cancer Sci. 100(9), 1612-1622 (2009).
94. Tojima Y, Fujimoto A, Delhase M et al. NAK is an IkB kinase-activating kinase. Nature 404(6779), 778-782 (2000).
95. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007).
96. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkB kinase a and NF-kB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18(51), 7389-7394 (1999).
97. Boehm JS, Zhao JJ, Yao J et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129(6), 1065-1079 (2007).
98. Seo SI, Song SY, Kang MR et al. Immunohistochemical analysis of NF-kB signaling proteins IKKe, p50/p105, p52/p100 and RelA in prostate cancers. APMIS 117(8), 623-628 (2009).
99. Alsayed Y, Leleu X, Leontovich A et al. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur. J. Haematol. 81(4), 298-303 (2008).
100. Hutti JE, Shen RR, Abbott DW et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKe promotes cell transformation. Mol. Cell 34(4), 461-472 (2009).
101. Wan F, Anderson DE, Barnitz RA et al. Ribosomal protein S3: a KH domain subunit in NF-kB complexes that mediates selective gene regulation. Cell 131(5), 927-939 (2007).
102. Fenner BJ, Scannell M, Prehn JH. Identification of polyubiquitin binding proteins involved in NF-kB signaling using protein arrays. Biochim. Biophys. Acta 1794(7), 1010-1016 (2009).
103. Bruno ME, Borchers CH, Dial JM et al. Effects of TCDD upon IkB and IKK subunits localized in microsomes by proteomics. Arch. Biochem. Biophys. 406(2), 153-164 (2002).
104. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kB activation: from bench to bedside. Exp. Biol. Med. (Maywood), 233(1), 21-31 (2008).
105. Sandhu C, Hewel JA, Badis G et al. Evaluation of data-dependent versus targeted shotgun proteomic approaches for monitoring transcription factor expression in breast cancer. J. Proteome Res. 7(4), 1529-1541 (2008).